Trial Details
Nivolumab + TKI + Bempegaldesleukin
Area of Research: Advanced or mRCC
Phase 1/2

A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread

Brief Summary:

The purpose of this study is to first, in Part 1, to determine the safety of nivolumab, bempegaldesleukin (BEMPEG: NKTR-214), and Tyrosine Kinase Inhibitor (TKI) combination and then, in Part 2, to evaluate the effectiveness of nivolumab, bempegaldesleukin, and cabozantinib when compared with nivolumab and cabozantinib in participants with previously untreated kidney cancer that has advanced or has spread.

For more information, please contact the recruiting sites directly.
If there is no contact information, please email: The first line of the email MUST contain the NCT # and Site #.

54 locations available.

Log In

Log in below to access your account on BMS Science or Bolder Science. If you have an existing Bolder Science account, please use your login credentials for that account here.

Don't have an account? Sign Up


Please enter your email address.

You will receive a link to create a new password via email.

Log In


Create Account

Use the form below to create one account that will be used across both BMS Science and Bolder Science. Clinical trials that you save on either site will be shown together on your dashboard on Bolder Science. If you already have an account, you can log in here.

  • 8 characters minimum
  • First character cannot be a number
  • Last character cannot be a number